



Thor Medical ASA: First Customer Delivery Completed from AlphaOne

5.8.2026 07:00:00 CEST | Thor Medical ASA | Non-regulatory press releases

Thor Medical, a leading supplier of high-purity isotopes to the radiopharmaceutical industry, today announced that it has completed its first customer delivery of high-purity Thorium-228 from the AlphaOne production facility at Herøya Industrial Park.

The delivery follows the production start announced last week and marks the beginning of commercial supply from AlphaOne.

"Commercial production marks the start of industrial-scale manufacturing. Our first customer delivery marks the beginning of our industrial-scale business," said Jasper Kurth, Chief Executive Officer of Thor Medical. "This delivery demonstrates that we have successfully transitioned from building production capacity to serving customers from our first industrial-scale facility. As we continue to ramp production, we are well positioned to support the growing demand for high-purity isotopes in targeted alpha therapies."

Thor Medical expects customer deliveries from AlphaOne to continue, while production volumes gradually increase in line with the ramp-up plan towards 21,000 patient dose equivalents after three years.

Contacts

- Mathias Nilsen Reierth, Head of Communications and Corporate Affairs, +47 988 05 724, mathias.reierth@thormedical.com

About Thor Medical ASA

ABOUT THOR MEDICAL ASA

Thor Medical is a leading supplier of high-purity isotopes to the radiopharmaceutical industry. The Company's proprietary production platform combines advanced separation technology with industrial-scale manufacturing capacity to deliver a reliable, scalable and cost-efficient supply of alpha-emitting radioisotopes. Thor Medical supports radiopharmaceutical companies from early-stage development to commercialization enabling scale-up of next-generation targeted cancer therapies.

Thor Medical's product portfolio includes lead-212 (Pb-212) and its precursor isotopes thorium-228 (Th-228) and radium-224 (Ra-224). Based on naturally occurring thorium, Thor Medical's production process requires neither irradiation nor nuclear reactors, providing significant cost advantages while minimizing radioactive waste.

Guided by its vision to become a world-leading enabler for targeted cancer therapies, Thor Medical is committed to improving millions of lives by powering the next generation of precision cancer treatment with high-purity isotopes.

Thor Medical is headquartered in Oslo, Norway, and listed on the Oslo Stock Exchange under the ticker symbol TRMED. For more information, visit www.thormedical.com.

Attachments

- [Download announcement as PDF.pdf](#)